CURIS presentations mark width of the target platform of cancer at 102nd AACR Annual meeting 2011

Current article ratings:
Patients / public:healthcare Prof:
CURIS, Inc. (NASDAQ: CRIS), a drug development company, which announced the development of the next generation of targeted small molecule drug candidates for the treatment of cancer, the submission of data in three poster presentations on the 102nd American Association for cancer research (AACR) annual meeting in OrlandoApril 2-6, 2011 in Florida.

"The data, which we presented at AACR this year show the versatility and breadth of our proprietary cancer platform," said Daniel Passeri, Curis President and Chief Executive Officer. "We believe that the potency and differentiability our product candidates of Curis's approach to the development of novel anti-cancer agents and on to review demonstrate that our proprietary and platform partners based on strong scientific justification."

The company characterization Preclinical data reported three drug development candidates, the cancer signaling networks aimed. The data show that Curis cancer platform can be been used a number of highly differentiated small molecule inhibitors for cancer with different functions to generate molecular composition and possible therapeutic utility in several cancer indications.

CUDC-101

Jing Wang, PhD., scientist, molecular and cell biology, presented a poster entitled "potential benefits of the CUDC 101, a multi-related HDAC, EGFR and HER2 inhibitor, on the prevention of drug resistance and tumor metastasis." The presentation highlighted data indicating that erlotinib resistant cancer cells and cancer cells are home to MET amplification are sensitive to the treatment of CUDC-101. In addition reduces CUDC-101 migration, invasion and epithelial-mesenchymal transition of cells suggests in vitro on, that it may at the same time suppress the potential to overcome tumor growth and metastasis and drug resistance.

CUDC-101 the lead of drug candidates by Curis is network-related cancer programs and is designed to epidermal growth factor receptor (EGFR), epidermal growth factor 2 (HER2) inhibit and histone deacetylase (HDAC). Review of CUDC-101 in a phase I study in patients with solid tumors advanced, refractory completed was, and initiated Curis has a phase IB expansion study in breast, stomach, head and neck, liver and non-small cell lung cancer. CURIS believes that CUDC-101 as an example for network-related approach of the company, which aims, by attacking cancer cells at several points of intervention to improve the therapeutic effects and durability of the clinical response.

CUDC-907

The second presentation focused on Curis latest molecule for clinical development, CUDC-907 selected. This presentation was given by Rudi Bao, m.d., PhD., Senior Director, oncology and was entitled "anti-tumor activity one dual PI3-k and HDAC inhibitor into hands of matologische cancer models". CUDC-907 to potently inhibit Phosphatidylinositol-3-kinase (PI3-k) and HDAC INHIBITORS, the combination of the

CURIS scientists believe have the synergetic interaction against cancer cells. Presented data also show that CUDC-907 potent reference in distributing houses assays of matologische connections and survival proved way inhibits Upregulated often to PI3-k inhibition. It also showed that in-vitro demonstrates his ability induced apoptosis CUDC-907 in low concentrations, multiple nodes survival pathways as a result of the epigenetic change by inhibiting the (not kinase) HDAC INHIBITORS aim to suppress. On the other hand the majority of the cancer cells are treated with a single aim of PI3-k inhibitor without prejudice.

The presented data shows further that CUDC-907 high exposure, a long half-life in the tumor tissue and oral bioavailability in preclinical models, shows what promising antiproliferative and Pro-apoptotic activity in hands of matologische cancer models.

Debio 0932

The third presentation was by Xiong CAI, PhD., Vice President of medicinal chemistry titled, "design and synthesis of Imidazopyridine derivatives as novel inhibitors of HSP90 for the treatment of cancer." This presentation highlights the discovery of Debio 0932 (formerly CUDC-305), which is a partnership with Debiopharm group. Dr. CAI presentation summarizes in detail design, synthesis and comprehensive structure activity relationships in the course of the campaign medicinal chemistry that identifies led to the selection of Debio 0932 for clinical development. Debio 0932 is an orally bioavailable small molecule inhibitor of heat shock protein 90 (HSP90), the currently used by the licensee Debiopharm is tested in a phase I study of the Curis.

Source:
CURIS, Inc.